Zobrazeno 1 - 10
of 757
pro vyhledávání: '"Kunihiko, Kobayashi"'
Autor:
Keita Miura, Takehito Shukuya, Naoki Furuya, Ryo Morita, Akira Kisohara, Atsuto Mouri, Satoshi Watanabe, Hisashi Tanaka, Aya Hirata, Taiki Hakozaki, Kosuke Hamai, Naoko Matsumoto, Kana Watanabe, Hironori Ashinuma, Eisaku Miyauchi, Koji Sugano, Shinobu Hosokawa, Koji Amano, Satoshi Morita, Kunihiko Kobayashi, Makoto Maemonodo, Kazuhisa Takahashi
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 6, Pp 2618-2628 (2024)
ABSTRACT Background Cancer cachexia complicates advanced non‐small cell lung cancer (NSCLC); however, it remains unclear how often cachexia occurs and how it affects the course of chemotherapy in patients receiving first‐line systemic therapy. Me
Externí odkaz:
https://doaj.org/article/2bd96d96f73f40fa8b85b8d8ecdb6499
Autor:
Kosuke Hashimoto, Kyoichi Kaira, Hisao Imai, Ou Yamaguchi, Atsuto Mouri, Ayako Shiono, Yu Miura, Kunihiko Kobayashi, Hiroshi Kagamu, Ichiei Kuji
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Two-deoxy-2-[fluorine-18]-fluoro-d-glucose (18F-FDG) positron emission tomography (PET) is useful for detecting malignant lesions; however, the clinical significance of cardiac 18F-FDG uptake in patients with cancer remains unclea
Externí odkaz:
https://doaj.org/article/449e6de7ae8843a09579cd9494df971a
Autor:
Keita Miura, Ou Yamaguchi, Keita Mori, Atsushi Nakamura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga, Daisuke Arai, Hiroaki Kodama, Kunihiko Kobayashi, Kyoichi Kaira
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Ramucirumab plus docetaxel (RD) can cause febrile neutropenia (FN), which frequently requires the prophylactic administration of pegfilgrastim. However, the effects of prophylactic pegfilgrastim on FN prevention, therapeutic efficacy, and pr
Externí odkaz:
https://doaj.org/article/2b814dbbea994c51a018f1a190fff4f2
Autor:
Hirozumi Sano, Ryoji Kobayashi, Daisuke Suzuki, Masato Yanagi, Daiki Hori, Satoru Matsushima, Kunihiko Kobayashi
Publikováno v:
Pediatrics and Neonatology, Vol 65, Iss 1, Pp 23-30 (2024)
Background: A prospective evaluation of non-alcoholic fatty liver disease (NAFLD) during induction therapy for acute lymphoblastic leukemia (ALL) has not been performed. Herein, we prospectively investigated the frequency, risk factors, and outcomes
Externí odkaz:
https://doaj.org/article/1747f9c5e738499f9e9687f357ff7696
Autor:
Ou Yamaguchi, Keita Mori, Saori Takata, Kazuhiko Shibata, Kenichi Chikamori, Nozomu Kimura, Yoshiaki Nagai, Taku Nakagawa, Satoshi Igawa, Taishi Harada, Hiroshige Yoshioka, Hisashi Tanaka, Hitomi Nogawa, Hiroaki Satoh, Toshihiro Shiozawa, Kosuke Tsuji, Kunihiko Kobayashi, Kyoichi Kaira
Publikováno v:
Thoracic Cancer, Vol 15, Iss 2, Pp 163-171 (2024)
Abstract Background The factors that predict the clinical response to ramucirumab plus docetaxel (RD) after first‐line chemoimmunotherapy are unresolved. We explored whether the therapeutic efficacy of prior chemoimmunotherapy could predict the out
Externí odkaz:
https://doaj.org/article/69b23a7a31d74e76959dd39356a3e58f
Autor:
Takehiro Tozuka, MD, Yuji Minegishi, MD, PhD, Ou Yamaguchi, MD, PhD, Kana Watanabe, MD, Yukihiro Toi, MD, Ryota Saito, MD, PhD, Yoshiaki Nagai, MD, PhD, Yosuke Tamura, MD, PhD, Tetsuaki Shoji, MD, PhD, Haruka Odagiri, MD, Noriyuki Ebi, MD, Kosuke Sakai, MD, PhD, Nobuhiro Kanaji, MD, PhD, Makoto Izumi, MD, Sayo Soda, MD, PhD, Satoshi Watanabe, MD, PhD, Satoshi Morita, PhD, Kunihiko Kobayashi, MD, PhD, Masahiro Seike, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100655- (2024)
Introduction: Immune checkpoint inhibitor (ICI)–based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival benefit of upfront radiotherapy for brain metastases (BMs) in patients with NSCLC who
Externí odkaz:
https://doaj.org/article/266c2a21ca60472ab272511e35e74652
Autor:
Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Kunihiko Kobayashi, Tomonori Kawasaki, Masanori Yasuda, Hiroshi Kagamu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 29, Pp 2950-2961 (2023)
Abstract Background Vascular endothelial growth factor (VEGF) has been identified as one of the resistant mechanisms to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs). However, the relationship between the efficacy of osi
Externí odkaz:
https://doaj.org/article/fece6ef98b054e98ae461b7a3a7353f3
Autor:
Hirozumi Sano, Ryoji Kobayashi, Satoru Matsushima, Daiki Hori, Masato Yanagi, Daisuke Suzuki, Go Ohba, Hiroshi Yamamoto, Kunihiko Kobayashi
Publikováno v:
Clinical Pediatric Hematology-Oncology, Vol 30, Iss 1, Pp 21-24 (2023)
Nephroblastomatosis (NBM) is a precursor of Wilms tumor. We herein report a case in which Wilms tumor was initially suspected and the affected kidney was removed. The tumor was subsequently diagnosed as intralobar NBM and a favorable outcome was achi
Externí odkaz:
https://doaj.org/article/05a5785abd4d4e34a748d863a0aa2622
Autor:
Kyoichi Kaira, Ou Yamaguchi, Tomonori Kawasaki, Kousuke Hashimoto, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Kobayashi, Masanori Yasuda, Hiroshi Kagamu
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Aim Tumor-infiltrating lymphocytes (TILs) in the tumor and stroma are expected to accurately predict the efficacy of programmed death-1 (PD-1) blockade therapy. However, little is known about the prognostic significance of TILs in first-line
Externí odkaz:
https://doaj.org/article/51df83129f1f4f2b811f207816e4829f
Autor:
Ou Yamaguchi, Kazuyuki Atarashi, Kenichi Yoshimura, Ayako Shiono, Atsuhito Mouri, Fuyumi Nishihara, Yu Miura, Kosuke Hashimoto, Yoshiaki Miyamoto, Hitoshi Uga, Nobuo Seki, Tomoko Matsushima, Norihiro Kikukawa, Kunihiko Kobayashi, Kyoichi Kaira, Hiroshi Kagamu
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Biomarkers that can accurately predict the efficacy of immune checkpoint inhibitors (ICIs) against programmed death 1 (PD-1) ligand in cancer immunotherapy are urgently needed. We have previously reported a novel formula that pred
Externí odkaz:
https://doaj.org/article/522b2b0c6666437e9f2d9288e7eef883